Skip to main content
GutCited

오메가-3 지방산(EPA/DHA) 그림

3 동료 심사 연구의 그림

전체 생강 아연 이눌린 커큐민 락타아제 베르베린 차전자피 비피도박테리움 롱검 비피도박테리움 락티스 비피도박테리움 비피덤 사카로마이세스 보울라디 락토바실루스 가세리 락토바실루스 플란타룸 락토바실루스 애시도필루스 부티레이트(나트륨/칼슘 부티레이트) 페퍼민트 오일 바실루스 코아굴란스 췌장효소(판크렐리파아제) 알로에 베라(내엽 젤) 알파-갈락토시다아제 소 초유 오메가-3 지방산(EPA/DHA) 비타민 A 비타민 D 프럭토올리고당(FOS) 갈락토올리고당(GOS) L-글루타민 중쇄중성지방(MCT 오일) N-아세틸시스테인(NAC)
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 1. Outline of the pathways of synthesis for the n-3 and n-6 polyunsaturated fatty acids eicosanoids and the specialised pro-resolving mediators. AA, arachidonic acid; ALA, α-linolenic acid; COX, cyclooxygenase; CYTP450, cytochrome P450 enzymes; DHA
Figure 5 Diagram

N-3 and n-6 polyunsaturated fatty acids follow distinct biosynthetic pathways to produce eicosanoids and specialized pro-resolving mediators. This diagram outlines the synthesis routes from alpha-linolenic acid and arachidonic acid through COX and cytochrome P450 enzymes to their bioactive lipid products.

The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A …

Figure 2. The n-3 polyunsaturated fatty acid targets of intestinal innate immunity. ALA, α-linolenic acid; CARD, caspase recognition domain; COX, cyclooxygenase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GPR, G-protein coupled receptor; ICAM,
Figure 6 Diagram

N-3 polyunsaturated fatty acids modulate intestinal innate immunity through multiple receptor and signaling targets. This diagram maps the interactions of DHA and EPA with G-protein coupled receptors, COX enzymes, and caspase recognition domains in intestinal immune cells.

The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A …

Figure 3. The immuno-suppressive and immuno-resolving approaches of inflammatory bowel disease treatment. AZA, azathioprine; PUFA, polyunsaturated fatty acid; TNF, tumour necrosis factor.
Figure 7 Diagram

Current IBD treatments employ both immuno-suppressive and immuno-resolving strategies. This diagram contrasts conventional therapies (azathioprine, anti-TNF agents) with emerging PUFA-based approaches that promote active resolution of intestinal inflammation.

The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A …